Leiomyosarcoma Clinical Trial
Official title:
A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
This is an open-label (patients will know the names of the study drugs they receive), randomized (patients will be assigned by chance to receive 1 of 2 treatment schedules with trabectidin) study designed to examine the the survival, safety, and pharmacokinetics (blood levels) trabectedin when administered to patients with 2 types of cancer (Liposarcoma or Leiomyosarcoma) who have received treatment with other anti-cancer therapy (Anthracycline and/or Ifosfamide). Trabectedin (also referred to as Yondelis) is a drug being developed to treat patients with cancer. Yondelis will be administered intravenously (i.v.) via a central catheter (tube) into a central vein once a week (0.58 mg/m2 as a 3-hour infusion on Days 1, 8, and 15 of each 28-day treatment cycle) or once every 3 weeks (1.5 mg/m2 administered as a 24-hour infusion on Day 1 of every 21-day treatment cycle) until disease progression. Patients in each arm will be pretreated with 20 mg of dexamethasone i.v. 30 minutes prior to each infusion. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04535271 -
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
|
Phase 2 | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT06088290 -
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
Completed |
NCT01442662 -
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
|
Phase 2 | |
Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05548179 -
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
|
||
Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
Active, not recruiting |
NCT04624178 -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
|
Phase 2 | |
Terminated |
NCT03959033 -
Patient Reported Outcome Measures (PROMs) With Trabectedin
|
||
Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01956084 -
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
|
Phase 1 | |
Completed |
NCT01426633 -
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
|
Phase 1 | |
Completed |
NCT00400569 -
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT05080790 -
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
|
Phase 2 |